titis media is a common t and often troublesome infection to treatespecially in the young, otitis-prone child. Prior to the availability of antimicrobial agents, otitis media and its complications were a common cause of hospital admission to pediatric services. Mastoiditis, hearing loss, and intracranial spread of infection were not uncommon complications of infection of the middle ear. The treatment of otitis media cannot be trivialized.
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Controversies about the treatment of otitis media are many; they include whether otitis media should always be treated with an antimicrobial agent. Reviews of placebo-controlled studies of the antimicrobial treatment of otitis media suggest that as many as 60% to 75% of cases of acute otitis media resolve without antimicrobial therapy.' This likely reflects a significant proportion of viral infections, as well as true clearing of some bacterial infections. With such high spontaneous cure rates, studies to evaluate new therapies are difficult. Studies with small numbers of cases lack the statistical power to detect clinically relevant differences between therapies. Very large num-bers of subjects are required in order to attain adequate power to show an effect of treatment.
In selecting antimicrobial treatment for this infection, pediatricians should take into account such factors as palatability, ease of giving therapy, and side effects.
However, choice of an antimicrobial therapy must primarily be based on demonstration of efficacy. Only agents with in vitro activity against the organisms responsible for otitis media and with adequate bioavailability should be considered. Efficacy studies used to compare therapies must have adequate statistical power to take into account the very high spontaneous cure rate of this infection.
One way to avoid the need for huge numbers of cases is to select cases for clinical efficacy studies with known microbiology. This approach allows the exclusion of cases caused by viral pathogens. Comparisons among antimicrobial agents under these conditions can be expected to correlate with in vitro activity and bioavailability of the particular agents. Correlation between bacterial efficacy and clinical efficacy will be highest when true cases of bacterial infection are studied, decreasing the effect of spontaneous cure.~ Using this approach, it is possible to compare agents by pathogen.3 For example, in a review pooling several small studies, S. pneumoniae persisted in middle ear fluid in 89% of placebo-treated episodes of otitis media versus persistence with amoxicillin, 5%; cefaclor, 18%; cefixime, 26%; cefuroxime, 0%; and trimethoprim-sulfamethoxazole, 0%.~ (By these criteria, cefaclor would not appear to be a &dquo;gold standard&dquo; by which to compare a new therapy.) If no bacteriology is available, extremely large numbers of cases must be studied to attain clinical or statistical significance. Consider the criteria: that the new therapy will be deemed acceptable only if its cure rate can be demonstrated with 90% confidence (on = 0.10) to be within 5% of the standard therapy's cure rate. If one accepts a 90% probability ((3 = 0.10) that the 90% confidence limit for the difference in cure rates does not exceed 5%, and that the cure rate for the standard therapy is 90%, then 473 patients are needed per group.
However, rates of failure with many antimicrobial agents, such as cefaclor, are likely to be higher than 10%. If only an 80% cure rate is expected, then 840 patients are needed per group.~ 5 In light of these considerations, the paper, &dquo;Single-Dose Ceftriaxone Versus 10 Days of Cefaclor for Otitis Media,&dquo; by Chamberlain et al in this issue of Clinical Pediatrics is not convincing. With neither careful microbiological data nor with adequate numbers of patients studied, this study is of very limited value. In our opinion, this study, like many others published, lacks sufficient power to determine whether the new therapy is, in fact, better than placebo.
Ceftriaxone is an excellent antimicrobial agent, with an excellent spectrum of activity in vitro for the treatment of otitis media and excellent bioavailability. It is unclear, however, why only 1 day of therapy with even this excellent agent should be significantly better than placebo.
The treatment of otitis media is of great importance. Large numbers of children are treated each year, and the medical costs of the treatment of this infection are considerable. While amoxicillin and trimethoprim-sulfamethoxazole remain the most frequently prescribed agents for treatment of this infection, the clear spread of resistant organisms makes it necessary to find alternate therapies. Only studies with clinically significant data should be used to judge new approaches to this infection.
